Skip to content

EV / sales at other companies

Pfizer logo
PfizerPFE
3.5×+0.3×
Cardinal Health logo
Cardinal HealthCAH
0.2×0.0×
McKesson logo
McKessonMCK
0.3×0.0×
Cencora logo
CencoraCOR
0.2×0.0×
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
3.7×+1.0×
AbbVie logo
AbbVieABBV
7.5×+1.0×

Other financials

Income statement

See full
Revenue$722.5M+3.9%
Gross profit$320.1M+25.1%
Operating income$141.8M+41.3%
Net income$62.3M+411%
EPS (diluted)$0.19+375%

Balance sheet

See full
Cash & equivalents$197.7M+234%
Total debt$2.6B+17.7%
Total equity-$45.4M+65.5%
Total assets$3.5B+5.2%

Cash flow

See full
Operating cash flow-$26.7M-461%
CapEx$8.2M-37.9%
Free cash flow-$34.9M-507%

Valuation

See full
Market cap$5.17B+51.0%
Enterprise value$7.55B+33.4%
P/E42.4×
P/S1.7×+0.5×

Profitability

See full
Gross margin38.7%+2.0pp
Operating margin14.3%+1.6pp
Net margin4%+3.6pp
FCF margin7.9%-1.0pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity127.9×+119×
Current ratio2.5×+1.1×

Where this comes from

Calculated from Amneal Pharmaceuticals, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amneal Pharmaceuticals, Inc.'s ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amneal Pharmaceuticals, Inc.'s EV / sales?
Amneal Pharmaceuticals, Inc. (AMRX) reported EV / sales of 2.1× in Q1 2026.
How has Amneal Pharmaceuticals, Inc.'s EV / sales changed year-over-year?
Amneal Pharmaceuticals, Inc.'s EV / sales increased by 23.9% year-over-year, from 1.7× to 2.1×.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s EV / sales?
Over 5 years (2020 to 2025), Amneal Pharmaceuticals, Inc.'s EV / sales has grown at a 5.3% compound annual growth rate (CAGR), from 1.6× to 2.1×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.